Last update 07 May 2025

Andamertinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
苯甲酸安达替尼, PLB 1004, PLB-1004
+ [1]
Target
Action
antagonists
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationBreakthrough Therapy (China)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Locally Advanced Lung Non-Squamous Non-Small Cell CarcinomaPhase 3-30 Mar 2024
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3-30 Mar 2024
EGFR positive Non-squamous non-small cell lung cancerPhase 3
China
22 Mar 2024
Locally Advanced Lung Non-Small Cell CarcinomaPhase 2
China
07 Aug 2024
EGFR mutation MET positive Non-small Cell Lung CancerPhase 2
China
24 Jul 2024
EGFR ex20ins mutation in non-small cell lung cancerPhase 2
China
21 Jul 2023
EGFR-mutated non-small Cell Lung CancerPhase 2
China
13 Jun 2023
c-Met positive non-small cell lung cancerPhase 2
China
05 Jun 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
EGFR mutation MET positive Non-small Cell Lung Cancer
MET Overexpression | MET Amplification | EGFR Mutation
44
Vebreltinib 100mg plus PLB1004 160mg
biyovugfgc(khepvpokxc) = bjzqivmxsu klssrgyfdf (ggfvbupjlo )
Positive
10 Sep 2024
biyovugfgc(khepvpokxc) = mlrspvzlue klssrgyfdf (ggfvbupjlo )
AACR2023
ManualManual
Phase 1
Non-Small Cell Lung Cancer
Second line
EGFR Exon 20 Missense
-
ajraffevng(ttnogwlzqp) = qgjykwfxou mqrmhmwajw (qcyafrihgd )
Positive
14 Apr 2023
(EGFR Ex20ins mutations)
naldupfpri(dvytzssvql) = urmenmcsjw zmobzojkwm (zilozdcsou )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free